GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Accustem Sciences ACUT · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.13

0.00%

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Accustem Sciences

From its filings with the US Securities and Exchange Commission

SEC filings

Accustem Sciences is based in New York, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker ACUT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $1.8m. At that date it held total assets of $1.5m and shareholders' equity of −$3.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Mar 2022
Employees
4
Head office
5 PENN PLAZA, 19TH FLOOR, NEW YORK, NY, 10001
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Ms. Wendy BlosserChief Executive Officer, Director, since 2022$425,000
  • Ms. Keeren ShahChief Financial Officer
  • Mr. Joe FlanaganChief Business Officer$300,000
  • Mr. Gabriele CerroneDirector$66,000
  • Mr. John BrancaccioIndependent Director$50,000
  • Mr. Sean McDonaldIndependent Director$50,000
  • Mr. Willy SimonIndependent Director$50,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • AccuStem Sciences Inc employs 4 full-time employees with expertise in biotechnology.
  • StemPrintER is a 20-gene prognostic assay for luminal breast cancer patients.
  • The company holds licensing rights for the MicroRNA Signature Classifier test for lung nodules.

Weaknesses

  • The company has only 4 employees and limited resources for development.
  • AccuStem Sciences Inc went public on 1 March 2022 with a small market presence.
  • The firm's business is focused on a single product, StemPrintER, with limited diversification.

Opportunities

  • The US market offers significant growth potential for genomic testing in oncology care.
  • The MicroRNA Signature Classifier test can expand into lung cancer screening programs.
  • StemPrintER Sciences Limited provides a platform for future product development.

Threats

  • The biotechnology sector faces intense competition from larger firms with more resources.
  • Regulatory changes could impact the approval process for genomic tests.
  • The company's small size may hinder its ability to secure large-scale partnerships.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.